Yale Medicine Magazine profiles Colton-funded researchers using skin as a diagnostic and therapeutic entry point into autoimmune disease — from scleroderma antibody therapy to cancer-triggered bullous pemphigoid.
Colton-supported NYU researchers have found that autoantibodies can physically inactivate a key enzyme in over half of lupus nephritis patients — a non-genetic mechanism that could serve as a future biomarker and therapeutic target.
Yale immunologist Dr. Joseph Craft outlines the mission of the newly launched Colton Center for Autoimmunity — a cross-disciplinary initiative to translate autoimmune research into real-world diagnostics and treatments.
NYU Langone's Colton Center has funded seven new autoimmune pilot projects for 2019 — targeting myasthenia gravis, rheumatoid arthritis, and lupus — while earlier grants advance toward clinical diagnostics and therapies.
NYU Langone's Colton Center for Autoimmunity profiles its cross-disciplinary pilot research program — connecting researchers across rheumatology, immunology, genetics, and neuroimmunology to accelerate autoimmune disease breakthroughs.
